Assessment of Metabolic Response to Radioimmunotherapy (RIT) with Yttrium-90 (Y-90) Ibritumomab Tiuxetan in Patients with Relapsed or Refractory B-cell non-Hodgkin Lymphoma
Assessment of Metabolic Response to Radioimmunotherapy (RIT) with Yttrium-90 (Y-90) Ibritumomab Tiuxetan in Patients with Relapsed or Refractory B-cell non-Hodgkin Lymphoma(391 views) Storto G, Nardelli A, Pellegrino T, Perna F, De Falco T, Erra P, Ortosecco G, Castaldi E, Speranza A, Klain M, De Renzo A, Di Nuzzo C, Pace L, Rotoli B, Salvatore M
Paper type: Journal Article, Abstract, Conference,
Impact factor: 4.532, 5-year impact factor: 4.625
Url: Not available.
Keywords: Not available.
Affiliations: *** IBB - CNR ***
References: Not available.
Assessment of Metabolic Response to Radioimmunotherapy (RIT) with Yttrium-90 (Y-90) Ibritumomab Tiuxetan in Patients with Relapsed or Refractory B-cell non-Hodgkin Lymphoma
Not available.
Assessment of Metabolic Response to Radioimmunotherapy (RIT) with Yttrium-90 (Y-90) Ibritumomab Tiuxetan in Patients with Relapsed or Refractory B-cell non-Hodgkin Lymphoma
Assessment of Metabolic Response to Radioimmunotherapy (RIT) with Yttrium-90 (Y-90) Ibritumomab Tiuxetan in Patients with Relapsed or Refractory B-cell non-Hodgkin Lymphoma